Esbriet

News

Ten years on, Roche jettisons InterMune and Esbriet in US

It's been 10 years since Roche bought InterMune for $8.3bn on the promise of its pulmonary fibrosis drug Esbriet. Now, it's sold the business.

News

NICE backs use of Boehringer's Ofev in IPF from diagnosis

Thousands more UK patients with idiopathic pulmonary fibrosis (IPF) will now be eligible for treatment with Boehringer Ingelheim's Ofev, following new guidance from health technology assess

News

PureTech challenges Roche's Esbriet in head-to-head IPF tria...

Roche's idiopathic pulmonary fibrosis (IPF) therapy Esbriet is already being squeezed by its main rival in the market, and could come under renewed pressure if another competitor from PureT

Ten years on, Roche jettisons InterMune and Esbriet in US

NICE backs use of Boehringer's Ofev in IPF from diagnosis

PureTech challenges Roche's Esbriet in head-to-head IPF tria...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Editor's Picks